ISDA

Deposition Date 2016-07-23

Release Date 2017-05-31

Last Version Date 2023-10-04

Entry Detail

PDB ID:

5KZ7

Keywords:

Transferase/Transferase Inhibitor

Title:

Mark2 complex with 7-[(1S)-1-(4-fluorophenyl)ethyl]-5,5-dimethyl-2-(3-pyridylamino)pyrrolo[2,3-d]pyrimidin-6-one

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.20 Å

R-Value Free:

0.29

R-Value Work:

0.22

R-Value Observed:

0.22

Space Group:

P 61

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Serine/threonine-protein kinase MARK2
Gene (Uniprot):MARK2
Chain IDs:A, B
Chain Length:346
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q7KZI7 Pfam ID:PF00069, PF00627

Ligand Molecules

6Z2

Primary Citation

Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.

Katz, J.D, Haidle, A, Childers, K.K, Zabierek, A.A, Jewell, J.P, Hou, Y, Altman, M.D, Szewczak, A, Chen, D, Harsch, A, Hayashi, M, Warren, L, Hutton, M, Nuthall, H, Su, H.P, Munshi, S, Stanton, M.G, Davies, I.W, Munoz, B, Northrup, A.Show

Bioorg. Med. Chem. Lett. 27 114 120 (2017)

PMID: 27816515 DOI: 10.1016/j.bmcl.2016.08.068

Abstact

The initial structure activity relationships around an isoindoline uHTS hit will be described. Information gleaned from ligand co-crystal structures allowed for rapid refinements in both MARK potency and kinase selectivity. These efforts allowed for the identification of a compound with properties suitable for use as an in vitro tool compound for validation studies on MARK as a viable target for Alzheimer's disease.

Legend

Protein

Chemical

Disease

Primary Citation of related structures